A chronic lung infection with Pseudomonas aeruginosa is associated with an increased exacerbation and mortality rate in people affected by bronchiectasis. Inhaled antibiotics are frequently used in clinical practice to treat chronic infections with this bacterium. The PROMIS-I and PROMIS-II studies investigated the efficacy and safety of 12-month inhaled colistimethate sodium administration in patients with bronchiectasis and chronic P. aeruginosa infection.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- "Patients W.A.I.T. Indicator"
Access to new drugs is becoming increasingly difficult
- Cardiometabolic research
The liver-heart axis in the pathogenesis of cardiometabolic diseases
- ASCO 2025
Supportive therapies for greater adherence and compliance
- Heart rhythm
From harmonious symphony to age-related dissonance
- Precision therapy
Targeted MET inhibition after progression with osimertinib
- Chronic cough
Differential diagnostic detective work and trial therapies
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Glomerulonephritis: IgA nephropathy